264 related articles for article (PubMed ID: 32512287)
21. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
[TBL] [Abstract][Full Text] [Related]
22. Development of RISS in two patients with NMOSD undergoing rituximab treatment: a case report.
Ersöz AS; Yaşargün DÖ; Mısırlı CH
Acta Neurol Belg; 2024 Jun; 124(3):1041-1042. PubMed ID: 37904077
[No Abstract] [Full Text] [Related]
23. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic.
Abboud H; Zheng C; Kar I; Chen CK; Sau C; Serra A
Mult Scler Relat Disord; 2020 Sep; 44():102249. PubMed ID: 32526698
[TBL] [Abstract][Full Text] [Related]
24. Demyelinating syndrome in systemic sclerosis and neuromyelitis optica.
Deeb K; Eby J; Labault-Santiago J
BMC Neurol; 2019 Oct; 19(1):234. PubMed ID: 31607267
[TBL] [Abstract][Full Text] [Related]
25. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
[TBL] [Abstract][Full Text] [Related]
26. Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders.
Luo JJ; Lv H; Sun W; Zhao J; Hao HJ; Gao F; Huang YN
Mult Scler Relat Disord; 2016 Jul; 8():74-7. PubMed ID: 27456878
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
28. Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.
Tobin WO; Pittock SJ
JAMA Neurol; 2015 Sep; 72(9):974-7. PubMed ID: 26168370
[No Abstract] [Full Text] [Related]
29. COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.
Barzegar M; Mirmosayyeb O; Ebrahimi N; Bagherieh S; Afshari-Safavi A; Hosseinabadi AM; Shaygannejad V; Asgari N
Mult Scler Relat Disord; 2022 Jan; 57():103359. PubMed ID: 35158468
[TBL] [Abstract][Full Text] [Related]
30. High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
Klawiter EC; Bove R; Elsone L; Alvarez E; Borisow N; Cortez M; Mateen F; Mealy MA; Sorum J; Mutch K; Tobyne SM; Ruprecht K; Buckle G; Levy M; Wingerchuk D; Paul F; Cross AH; Jacobs A; Chitnis T; Weinshenker B
Neurology; 2017 Nov; 89(22):2238-2244. PubMed ID: 29093070
[TBL] [Abstract][Full Text] [Related]
31. Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Jang H; Park NY; Kim Y; Jung JY; Lee MY; Hyun JW; Kim HJ
Eur J Neurol; 2020 Aug; 27(8):1546-1555. PubMed ID: 32320109
[TBL] [Abstract][Full Text] [Related]
32. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
Bejerot S; Hesselmark E; Mobarrez F; Wallén H; Hietala MA; Nybom R; Wetterberg L
J Med Case Rep; 2019 Jan; 13(1):27. PubMed ID: 30696485
[TBL] [Abstract][Full Text] [Related]
33. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
34. Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.
Stavrou M; Francis L; Tshuma N; Schmierer K
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29794010
[TBL] [Abstract][Full Text] [Related]
35. Overlapping demyelinating syndrome (Neuromyelitis optica spectrum disorders NMOSD with anti-NMDA receptor encephalitis); A case report.
Sinani AA; Maawali SA; Alshekaili J; Kindi MA; Ramadhani KA; Khabouri JA; Nadeem A; Salti AA
Mult Scler Relat Disord; 2020 Jul; 42():102153. PubMed ID: 32413838
[TBL] [Abstract][Full Text] [Related]
36. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
37. Neuromyelitis optica spectrum disorders in Iran.
Eskandarieh S; Nedjat S; Azimi AR; Moghadasi AN; Sahraian MA
Mult Scler Relat Disord; 2017 Nov; 18():209-212. PubMed ID: 29141812
[TBL] [Abstract][Full Text] [Related]
38. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
[No Abstract] [Full Text] [Related]
39. Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant
Zhang W; Jiao Y; Jiao J; Jin M; Peng D
Front Immunol; 2022; 13():1047992. PubMed ID: 36569904
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
